Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

How sex hormones affect the age- and sex-related benefits of a low-calorie diet

Official title: GendAge Weight Loss Study: Sex Hormones as Regulators of the Age- and Sex-dependent Benefits of Caloric Restriction

Run by University of Aberdeen · NCT07065643 · Data updated 2026-11-12

This trial tests whether sex hormones explain why adults of different ages and sexes lose fat and get different health benefits when they follow a low-calorie diet.

More Healthy Aging trials

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment75 (estimated)
SponsorUniversity of Aberdeen
Academic / other
Locations1 site (Aberdeen)
StatusRecruiting
StartedJuly 9, 2025
Main results expectedDecember 2027
Study endsDecember 2027
Registry record updatedJuly 18, 2025
Trial IDNCT07065643 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Healthy adults aged over 18 with BMI 27–45 kg/m2, including men and women divided into younger (≤40) and older (55–65) groups, with older women both on and off oestrogen HRT.

Probably not a fit

People outside the specified age or BMI ranges, those taking excluded medications (for example weight-loss drugs, certain psychotropics, or diabetes medications), or those with significant medical issues are unlikely to gain benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study enrolls healthy adults with BMI 27–45 kg/m2 and places them on a controlled diet program with an initial maintenance phase followed by a supervised weight-loss (calorie-restricted) phase. Participants are grouped by sex and age (younger ≤40 and older 55–65) with older women split by menopausal status and HRT use, allowing comparison across five cohorts. Researchers will measure body composition, blood glucose and metabolic markers, and sex hormone levels to link hormonal status with changes in fat loss and metabolic outcomes. People on excluded medications or with disqualifying health conditions are screened out to reduce confounding effects.

Why it matters

Potential benefit: If successful, the results could help tailor weight-loss advice by age, sex, and menopausal/HRT status to improve fat loss and metabolic health for different groups.

How similar studies have gone: Prior animal studies and some human work suggest sex differences in response to calorie restriction, but directly testing the role of sex hormones and HRT in middle-aged adults is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria

* Adults (aged over 18years) who are healthy but overweight/obese (BMI 27-45kg/m2) males and females as:
* 15 women (age 40 or less years)
* 15 men (age 40 or less years)
* 15 women (age 55-65 years) in menopause\*; not taking Hormone Replacement Therapy (HRT)
* 15 men (age 55-65 years)
* 15 women (age 55-65 years) in menopause; taking HRT\*\*

  * menopause definition is no menstrual period for 12 months \*\*HRT inclusion criteria - women will have continuously taken oestrogen HRT for 24 months

Exclusion criteria:

Potential volunteers will be asked to fill in a health questionnaire at the screening visit to assess their suitability for the study. This information will allow us to exclude participants.

Medication exclusion criteria, current use :-

• weight loss medication (e.g. GLP agonists), β-blockers, antihistamines, antipsychotics, benzodiazepines, barbiturates, melatonin, Ritalin, modafinil, soporifics, hypnotics, antiepileptic drugs, diabetes medication (e.g. metformin or insulin).

Self-reported medical exclusion criteria:

* Females who are planning to be pregnant, are pregnant or are breastfeeding
* Anyone with coeliac disease or gluten intolerance or food allergy
* Anyone with diagnosed T1 or T2 diabetes
* Anyone suffering from a psychiatric disorder or any type of substance abuse

Other exclusion criteria

* Anyone following a vegetarian or vegan diet
* Anyone currently following a weight loss programme (that may be affecting lifestyle, physical activity \& diet) or undergone gastric band/reduction surgery; including GLP agonist (e.g. Semaglutide injection, Ozempic®).
* Anyone currently participating in another research study
* Anyone with unsuitable veins for blood sampling
* Anyone who is unable to fluently speak, read and understand English
* Anyone who is unable to comply to an alcohol-free diet for 6 weeks
* Anyone unable to give fully informed consent

Where it's running

  • Rowett Institute, University of Aberdeen
    Aberdeen, United Kingdom
    Recruiting

Study contacts

  • Principal investigator: Alexandra M Johnstone, Professor — Rowett Institute, University of Aberdeen
  • Study coordinator: Alexandra M. Johnstone, Professor
  • Email: alex.johnstone@abdn.ac.uk
  • Phone: 01224 438614

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.